Zacks Research Has Bearish Forecast for Bruker Q2 Earnings

Bruker Co. (NASDAQ:BRKR - Free Report) - Investment analysts at Zacks Research lowered their Q2 2025 earnings per share estimates for shares of Bruker in a research report issued on Wednesday, May 28th. Zacks Research analyst R. Department now expects that the medical research company will earn $0.43 per share for the quarter, down from their previous estimate of $0.57. The consensus estimate for Bruker's current full-year earnings is $2.69 per share. Zacks Research also issued estimates for Bruker's Q3 2025 earnings at $0.63 EPS, FY2025 earnings at $2.44 EPS, Q3 2026 earnings at $0.67 EPS and Q4 2026 earnings at $0.95 EPS.

Bruker (NASDAQ:BRKR - Get Free Report) last issued its quarterly earnings results on Wednesday, May 7th. The medical research company reported $0.47 earnings per share for the quarter, topping the consensus estimate of $0.46 by $0.01. Bruker had a return on equity of 21.01% and a net margin of 3.36%. The company had revenue of $801.40 million for the quarter, compared to the consensus estimate of $763.83 million. During the same quarter in the prior year, the business earned $0.53 EPS. Bruker's revenue was up 11.0% on a year-over-year basis.

Several other equities research analysts also recently weighed in on the company. UBS Group cut their price target on Bruker from $57.00 to $45.00 and set a "neutral" rating on the stock in a report on Thursday, May 8th. Stifel Nicolaus cut their price target on Bruker from $57.00 to $48.00 and set a "hold" rating on the stock in a report on Thursday, May 8th. The Goldman Sachs Group dropped their price objective on Bruker from $50.00 to $45.00 and set a "neutral" rating on the stock in a report on Thursday, May 8th. Wells Fargo & Company dropped their price objective on Bruker from $75.00 to $60.00 and set an "overweight" rating on the stock in a report on Thursday, April 17th. Finally, Guggenheim reiterated a "buy" rating on shares of Bruker in a report on Monday, February 24th. Six research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company's stock. Based on data from MarketBeat.com, Bruker currently has an average rating of "Hold" and a consensus price target of $59.10.

Bruker Stock Down 1.7%

NASDAQ BRKR traded down $0.63 during trading hours on Thursday, hitting $36.63. 1,470,266 shares of the company were exchanged, compared to its average volume of 1,614,427. The company has a 50 day moving average of $38.62 and a two-hundred day moving average of $49.01. The company has a quick ratio of 0.77, a current ratio of 1.60 and a debt-to-equity ratio of 1.15. Bruker has a 52-week low of $34.10 and a 52-week high of $72.94. The firm has a market cap of $5.55 billion, a price-to-earnings ratio of 48.20, a PEG ratio of 2.16 and a beta of 1.23.

Bruker Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, June 27th. Shareholders of record on Monday, June 16th will be given a dividend of $0.05 per share. The ex-dividend date of this dividend is Monday, June 16th. This represents a $0.20 dividend on an annualized basis and a yield of 0.55%. Bruker's payout ratio is 38.46%.

Institutional Trading of Bruker

A number of hedge funds have recently added to or reduced their stakes in BRKR. Pinnacle Bancorp Inc. acquired a new stake in Bruker during the 1st quarter worth approximately $29,000. Allworth Financial LP lifted its position in Bruker by 92.4% during the 1st quarter. Allworth Financial LP now owns 758 shares of the medical research company's stock worth $30,000 after acquiring an additional 364 shares during the period. Caitong International Asset Management Co. Ltd lifted its position in Bruker by 1,354.5% during the 1st quarter. Caitong International Asset Management Co. Ltd now owns 800 shares of the medical research company's stock worth $33,000 after acquiring an additional 745 shares during the period. Annis Gardner Whiting Capital Advisors LLC acquired a new stake in Bruker during the 1st quarter worth approximately $42,000. Finally, MassMutual Private Wealth & Trust FSB lifted its position in Bruker by 274.9% during the 1st quarter. MassMutual Private Wealth & Trust FSB now owns 1,091 shares of the medical research company's stock worth $46,000 after acquiring an additional 800 shares during the period. 79.52% of the stock is owned by institutional investors and hedge funds.

About Bruker

Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies.